Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2022 07:30 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients.PLX-R18 reduced...
March 08, 2022 07:12 ET | Source: Pluristem Therapeutics, Inc.

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”), and Tnuva Group (“Tnuva Group” or “Tnuva”),...
March 02, 2022 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem CEO Issues Shareholder Update

HAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief...
February 24, 2022 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

Pluristem officially closed a deal with Israel’s largest food brand Tnuva on February 24 2022, cementing an innovative partnership in the fast-growing industry of food techPluristem and Tnuva are...
January 10, 2022 03:00 ET | Source: Pluristem Therapeutics, Inc.

Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform

Collaboration uniquely combines Pluristem’s technological expertise in mass-scale, cost-effective, consistent cell production with Tnuva’s power multipliers in consumer-packaged goods, research and...
December 27, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced topline results from its...
November 15, 2021 07:10 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Having recruited patients in the U.S., Europe and Israel, the Company anticipates topline results in the third calendar quarter of 2022 The Company will host a Key Opinion Leader online event...
November 10, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform

HAIFA, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading biotechnology company, today announced that it has received approval for an...
September 22, 2021 08:15 ET | Source: Pluristem Therapeutics, Inc.

Pluristem CEO Issues Shareholder Update

HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief...
July 19, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors

HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof....